Yousif Matloub

Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Peter F. Coccia, Alberto S. Pappo, Lynda K. Beaupin et al. · Journal of the National Comprehensive Cancer Network · 2018 · 297 citations

Medicine, Counseling, Oncology +16

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

Neha Shah, D.-W. Kim, Hagop M. Kantarjian et al. · Haematologica · 2010 · 243 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0331

Kelly W. Maloney, Meenakshi Devidas, Cindy Wang et al. · Journal of Clinical Oncology · 2019 · 198 citations · Full text

Medicine, Oncology, Pediatrics +16

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion

Kimmo Porkka, H. Jean Khoury, Ronald Paquette et al. · Cancer · 2009 · 155 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +11

Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group

Yousif Matloub, Bruce Bostrom, Stephen P. Hunger et al. · Blood · 2011 · 148 citations · Full text

Medicine, Oncology, Pediatrics +11